[8-K] Quince Therapeutics, Inc. Reports Material Event

Quince Therapeutics, Inc. has regained compliance with Nasdaq’s continued listing standards.

Rhea-AI Filing Summary

Quince Therapeutics, Inc. has regained compliance with Nasdaq’s continued listing standards. Nasdaq staff reviewed the company’s Form 10-Q for the quarter ended March 31, 2026, which reported stockholders’ equity of $15,672,000, and determined that Quince now meets Nasdaq Listing Rule 5450(b)(1)(A).

This closes a prior deficiency notice issued on March 17, 2026, when Quince had failed to maintain a minimum market value of listed securities of $50,000,000 over 30 consecutive business days. Nasdaq has confirmed that the compliance matter is now closed and the company remains listed on the Nasdaq Global Select Market.

Positive

• Nasdaq compliance restored: Nasdaq staff confirmed Quince meets Listing Rule 5450(b)(1)(A) with stockholders’ equity of $15,672,000, closing a prior deficiency notice tied to the $50,000,000 market value requirement and removing immediate listing risk.

Negative

• None.

Insights

Equity market listing specialist

Nasdaq confirms Quince back in full compliance, removing near-term delisting risk.

Quince Therapeutics previously faced a Nasdaq deficiency notice for failing to maintain a $50,000,000 market value of listed securities over 30 days. That issue could have led to a downgrade or eventual delisting if unresolved.

Nasdaq’s May 20, 2026 letter confirms Quince now meets Listing Rule 5450(b)(1)(A) based on reported stockholders’ equity of $15,672,000 as of March 31, 2026. The matter is officially closed, meaning the company continues trading on the Nasdaq Global Select Market under existing terms.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Stockholders’ equity: $15,672,000 MVLS requirement: $50,000,000 Listing rule satisfied: Nasdaq Listing Rule 5450(b)(1)(A) +2 more

5 metrics

Stockholders’ equity $15,672,000 Reported in Form 10-Q for quarter ended March 31, 2026

MVLS requirement $50,000,000 Minimum market value of listed securities over 30 consecutive business days

Listing rule satisfied Nasdaq Listing Rule 5450(b)(1)(A) Used by Nasdaq to confirm continued listing compliance

Prior deficiency date March 17, 2026 Date Nasdaq notified Quince of MVLS non-compliance

Compliance confirmation date May 20, 2026 Date Nasdaq staff letter confirmed rule 5450(b)(1)(A) compliance

Key Terms

market value of listed securities, stockholders’ equity, Nasdaq Listing Rule 5450(b)(1)(A), continued listing requirements

4 terms

market value of listed securities financial

"failed to maintain a minimum market value of listed securities (“MVLS”) of $50,000,000"

Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.

stockholders’ equity financial

"reported stockholders’ equity of $15,672,000, the Company complies with Nasdaq Listing Rule"

Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.

Nasdaq Listing Rule 5450(b)(1)(A) regulatory

"the Company complies with Nasdaq Listing Rule 5450(b)(1)(A). Accordingly, the Company has regained compliance"

continued listing requirements regulatory

"the Company has regained compliance with Nasdaq’s continued listing requirements and this matter is now closed"

Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq issue did Quince Therapeutics (QNCX) previously face?

Quince previously received a Nasdaq notice for not maintaining a $50,000,000 market value of listed securities over 30 consecutive business days, a key requirement for continued listing on the Nasdaq Global Market.

How did Quince Therapeutics (QNCX) regain Nasdaq listing compliance?

Quince regained compliance after its Form 10-Q for the quarter ended March 31, 2026 reported stockholders’ equity of $15,672,000, satisfying Nasdaq Listing Rule 5450(b)(1)(A) based on equity instead of market value.

Which Nasdaq listing rule does Quince Therapeutics now satisfy?

Quince now complies with Nasdaq Listing Rule 5450(b)(1)(A), which focuses on stockholders’ equity. Nasdaq staff cited stockholders’ equity of $15,672,000 reported in the March 31, 2026 Form 10-Q as the basis for compliance.

Is the Nasdaq deficiency matter for Quince Therapeutics (QNCX) still open?

No. Nasdaq staff sent a letter dated May 20, 2026 stating that Quince complies with Nasdaq Listing Rule 5450(b)(1)(A). The company confirmed the continued listing matter is now closed by Nasdaq.

What financial figure was key to Quince Therapeutics’ Nasdaq compliance?

The key figure was stockholders’ equity of $15,672,000 reported in Quince’s Form 10-Q for the quarter ended March 31, 2026. Nasdaq used this amount to confirm compliance with Listing Rule 5450(b)(1)(A).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 05:06 PM EDT Learn about SEC filing dates

false 0001662774 0001662774 2026-05-20 2026-05-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2026

QUINCE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38890		90-1024039
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

611 Gateway Boulevard, Suite 273
South San Francisco, California		94080
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (415) 910-5717

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		QNCX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

As previously disclosed, on March 17, 2026, Quince Therapeutics, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company had failed to maintain a minimum market value of listed securities (“MVLS”) of $50,000,000 over the previous 30 consecutive business days, as required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A).

On May 20, 2026, the Company received a letter from the Staff stating that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which reported stockholders’ equity of $15,672,000, the Company complies with Nasdaq Listing Rule 5450(b)(1)(A). Accordingly, the Company has regained compliance with Nasdaq’s continued listing requirements and this matter is now closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Quince Therapeutics, Inc.
				By:		/s/ Dirk Thye
Date: May 21, 2026				Name:		Dirk Thye
				Title:		Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB